Phillip M Phd Nudelman Net Worth

The estimated Net Worth of Phillip M Phd Nudelman is at least $4.48 Million dollars as of 29 September 2015. Phillip Nudelman owns over 150,000 units of CTI BioPharma Corp stock worth over $3,110,362 and over the last 21 years Phillip sold CTIC stock worth over $1,365,380.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Phillip Nudelman CTIC stock SEC Form 4 insiders trading

Phillip has made over 19 trades of the CTI BioPharma Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently Phillip sold 150,000 units of CTIC stock worth $217,500 on 29 September 2015.

The largest trade Phillip's ever made was selling 200,000 units of CTI BioPharma Corp stock on 29 June 2012 worth over $116,000. On average, Phillip trades about 24,545 units every 76 days since 2004. As of 29 September 2015 Phillip still owns at least 342,174 units of CTI BioPharma Corp stock.

You can see the complete history of Phillip Nudelman stock trades at the bottom of the page.

What's Phillip Nudelman's mailing address?

Phillip's mailing address filed with the SEC is 12951 NE 9TH, , BELLEVUE, WA, 98005.

Insiders trading at CTI BioPharma Corp

Over the last 21 years, insiders at CTI BioPharma Corp have traded over $80,110,449 worth of CTI BioPharma Corp stock and bought 9,566,060 units worth $25,487,533 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... und Advisors Llc Orbi Med Capit.... On average, CTI BioPharma Corp executives and independent directors trade stock every 26 days with the average trade being worth of $1,223,687. The most recent stock trade was executed by Adam R Craig on 24 January 2023, trading 85,317 units of CTIC stock currently worth $71,666.

What does CTI BioPharma Corp do?

cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.

Complete history of Phillip Nudelman stock trades at CTI BioPharma Corp

CTI BioPharma Corp executives and stock owners

CTI BioPharma Corp executives and other stock owners filed with the SEC include:

• Dr. Adam R. Craig,
  Pres, CEO, Interim Chief Medical Officer & Director
• Dr. Adam R. Craig M.B.A., M.D., Ph.D.,
  Pres, CEO, Interim Chief Medical Officer & Director
• Bruce J. Seeley,
  Exec. VP & COO
• David H. Kirske,
  Exec. VP, CFO & Sec.
• James K. Fong,
  Sr. VP & Chief Commercial Officer
• Dr. Jennifer A. Smith,
  Sr. VP of Biometrics
• John Volpone,
  Sr. VP of Strategic Operations
• Bruce K. Bennett Jr.,
  Sr. VP Global Pharmaceutical Operations
• Jim Fong,
  Sr. VP of US Commercial Operations
• Ed Bell,
  Sr. Director of Investor Relations
• Partners L P/Ilbiotechnolog...,
  
• Fred Telling,
  Director
• Reed Vaughn Tuckson,
  Director
• Michael A Metzger,
  Director
• Richard L Love,
  Director
• David Ross Parkinson,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Matthew D Perry,
  Director
• Phillip M Phd Nudelman,
  Director
• Matthew Plunkett,
  EVP, Corporate Development
• Healthcare Sabaxter Interna...,
  
• Steven E Benner,
  EVP, Chief Medical Officer
• James K Fong,
  EVP & Chief Commercial Officer
• Laurent Fischer,
  Director
• Bruce J. Seeley,
  EVP, Chief Operating Officer
• Partners L P/Ilbiotechnolog...,
  
• Adam R Craig,
  President and CEO
• Jack W Singer,
  EVP, Research Program Chairman
• David Kirske,
  EVP, Chief Financial Officer
• Craig Philips,
  President
• Daniel G Eramian,
  EVP, Corporate Communications
• Jade Brown,
  EVP, Chief Business Officer
• James Canfield,
  Chief Administrative Officer
• Max Link,
  Director
• Louis A Bianco,
  EVP, Finance & Administration
• Erich Platzer,
  Director
• Richard Jr Leigh,
  Exec. V.P., General Counsel
• James A Bianco,
  President and CEO
• Jack L Bowman,
  Director
• Scott Stromatt,
  EVP, Clinical Dev & Reg Affair
• Steve Aselage,
  EVP, Global Commercial Ops
• Edward F Kenney,
  EVP, Chief Operating Officer
• Martin P Sutter,
  Director
• John M Jr Fluke,
  Director
• Silvano Spinelli,
  EVP, Development
• Mary Oneil Mundinger,
  Director
• John H Bauer,
  Director
• Karen Ignagni,
  Director
• Vartan Gregorian,
  Director
• Healthcare Sa Baxter,
  10% owner
• Diane L. Parks,
  Director
• Advisors Llc Orbi Med Capit...,